Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Trial details
- Registry ID
- NCT05147467
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLNCT05147467 | Ascentage Pharma Group Inc. | Phase 2 | Recruiting | 2026-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |